Arbovirus Testing Market Report: Market Size & Forecast 2026

Arbovirus testing refers to the suite of diagnostic tools and assays used to detect infections caused by arthropod-borne viruses, including dengue, Zika, chikungunya, West Nile, and yellow fever. The market was valued at approximately $732 million in 2025 and is expected to experience steady expansion through the early 2030s, supported by growing disease burden and improved diagnostic access. Demand is reinforced by government and institutional investment in outbreak preparedness and vector-borne disease control programs.

• •Market valued at roughly $732 million in 2025, with projections reaching approximately $991 million by the early 2030s.
• •Core technologies include ELISA-based tests and RT-PCR-based molecular assays, alongside emerging rapid diagnostic platforms.
• •Primary end users are diagnostic laboratories, hospitals, and research centers.

Rising global temperatures and shifting ecosystems have expanded the geographic range of mosquito and tick vectors, increasing exposure to arboviruses in previously unaffected regions. International travel and urbanization in tropical and subtropical zones further amplify transmission risks and testing demand. Advances in molecular diagnostics and point-of-care technologies are also improving detection speed and accuracy, encouraging broader clinical adoption.

• •Climate change and urbanization are extending the habitats of Aedes, Culex, and other vector species, raising infection rates.
• •Increased global travel and trade accelerate cross-border spread of arboviral diseases, prompting greater diagnostic vigilance.
• •Technological improvements in RT-PCR, ELISA, and immunoassays are lowering detection limits and reducing turnaround times.

The market is commonly segmented by test type, with ELISA-based assays holding a significant share due to their cost-effectiveness and widespread laboratory adoption, while RT-PCR-based tests are valued for their higher sensitivity and specificity. End-use segmentation highlights diagnostic laboratories as the largest segment, followed by hospitals and research institutions. Geographically, North America and Europe currently account for substantial market shares due to advanced healthcare infrastructure, while Asia-Pacific and Latin America represent the fastest-growing regions owing to high disease prevalence and improving diagnostic networks.

• •ELISA-based tests dominate in routine screening, whereas RT-PCR-based tests are preferred for confirmatory and early-stage diagnosis.
• •Diagnostic laboratories represent the largest end-use category, with hospitals and research centers also contributing meaningfully.
• •Asia-Pacific and Latin America are the most dynamic regional markets, driven by endemic disease burden and expanding healthcare access.

What are the recent trends and outlook?

Looking forward, the arbovirus testing market is expected to sustain double-digit growth through the early 2030s, supported by continued vector expansion, heightened pandemic awareness, and the integration of multiplex testing panels. Emerging markets will likely drive volume growth as diagnostic capacity improves, while developed regions will focus on adopting high-throughput and point-of-care platforms. Ongoing research into novel biomarkers and next-generation sequencing may further reshape testing approaches over the longer term.

• •Multiplex PCR panels and integrated syndromic testing solutions are gaining traction, allowing simultaneous detection of multiple arboviruses.
• •Point-of-care and rapid lateral flow tests are expected to expand access in resource-limited and outbreak settings.
• •Long-term innovation may include CRISPR-based diagnostics and next-generation sequencing applications for arbovirus surveillance.